<DOC>
	<DOCNO>NCT01013506</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use letrozole +/- goserelin ( latter pre-menopausal woman ) may fight breast cancer lower amount estrogen body make . OSI-906 erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . It yet know whether hormone therapy OSI-906 effective give without erlotinib hydrochloride treat hormone-sensitive metastatic breast cancer . PURPOSE : This phase II trial study well give hormone therapy together OSI-906 without erlotinib hydrochloride work treat hormone-sensitive patient metastatic breast cancer .</brief_summary>
	<brief_title>Phase 2 , Endocrine Therapy + OSI-906 With Without Erlotinib Hormone-sensitive Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine antitumor activity letrozole +/- goserelin ( latter pre-menopausal woman ) combination IGF-1R inhibitor OSI-906 without erlotinib hydrochloride , measure time progression , patient hormone-sensitive metastatic breast cancer . Secondary - To determine safety regimens patient . - To determine response rate patient treat regimen . - To measure circulate C-peptide , IGF-1 , IGFBP-3 level patient treat regimen . - To correlate expression IGF-IR , EGFR , HER2 , Y1316 Y1131 pIGF-1R , PTEN , S473 pAkt , pMAPK , S118 ( MAPK site ) , S167 ( Akt S6 site ) pER formalin-fixed paraffin block ( FFPB ) clinical outcome luminal A vs. luminal B subtypes breast cancer . - To correlate mutational status PI3K ( E542K , E545K , H1047R ) DNA extract FFPB fresh biopsy clinical outcome luminal A vs. luminal B subtypes breast cancer OUTLINE : This multicenter study . Stratification base previous exposure endocrine therapy : ( Arm I ) previous endocrine therapy complete adjuvant therapy &gt; 6 month prior study enrollment ; ( Arm II ) patient previous endocrine therapy metastatic setting metastatic recurrence within 6 month adjuvant endocrine therapy . - Arm I : Patients receive oral letrozole daily day 1-28 +/- subcutaneous goserelin* day 1 oral IGF-1R inhibitor OSI-906 twice daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients receive oral letrozole +/- subcutaneous goserelin* IGF-1R inhibitor OSI-906 arm I . Patients also receive oral erlotinib hydrochloride daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *Goserelin give premenopausal patient . Tumor tissue sample original diagnosis fresh biopsy tissue collect biomarker analysis study . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast carcinoma Stage IV disease No locally recurrent resectable disease No symptomatic brain metastasis History brain metastasis allow provided patient clinically stable &gt; 3 week completion radiotherapy AND take steroid therapeutic anticonvulsant CYP3A4 modifier Hormone receptor status : Estrogen receptor and/or progesterone receptor positive tumor immunohistochemistry ( IHC ) PATIENT CHARACTERISTICS : Pre postmenopausal ECOG performance status 01 Life expectancy ≥ 6 month ANC ≥ 1,250/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN ( ≤ 3 time ULN liver metastasis present ) For patient Gilbert syndrome , direct bilirubin measure instead total bilirubin SGOT SGPT ≤ 1.5 time ULN ( ≤ 3 time ULN liver metastasis present ) Alkaline phosphatase ≤ 1.5 time ULN ( ≤ 3 time ULN liver metastasis present ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study therapy Able swallow retain oral medication Baseline QTc ≤ 450 msec No invasive cancer within past 5 year except completely resect basal cell squamous cell skin cancer successfully treat cervical carcinoma situ No malabsorption syndrome significantly affect gastrointestinal function No diabetes , fast glucose &gt; 150mg/dL , receive ongoing antihyperglycemic therapy No concurrent uncontrolled illness include , limited , follow : Ongoing active infection require parenteral antibiotic Impaired lung function ( i.e. , COPD lung condition require oxygen therapy ) Symptomatic congestive heart failure ( NYHA class III IV heart disease ) Unstable angina pectoris , angioplasty , stenting , myocardial infarction within past 6 month Uncontrolled hypertension , define systolic BP &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg two consecutive measurement take ≥ 1 week apart , despite adequate medical support Clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment ) Psychiatric illness and/or social situation would compromise patient safety limit compliance study requirement , include maintenance compliance/pill diary PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 2 week since prior investigational drug No 4 prior chemotherapy treatment metastatic setting Does include endocrine therapy singleagent biologic therapy No concurrent CYP3A4 CYP1A2 modifiers No concurrent anticancer therapy , include chemotherapy , radiotherapy , surgery , immunotherapy , hormonal therapy , biologic therapy Concurrent radiotherapy painful bone metastasis area impede bone fracture allow provide radiotherapy initiate study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>